Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 2/3 2Phase 1/2 1Phase 1 1

Status

Completed 8Unknown 7Recruiting 4Suspended 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Phase I: To Determine the Maximum Tolerated Dose (MTD) 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × S 1 (combination) × Clear all
NCT01106066 2013-06-14

Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT

Samsung Medical Center

Phase 1/2 Terminated
30 enrolled

Phase I: To Determine the Maximum Tolerated Dose (MTD)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡